Tenax Therapeutics, Inc.TENXNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank93
5Y CAGR+159.2%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
+159.2%/yr
Long-term compound
Percentile
P93
Near historical high
vs 5Y Ago
117.1x
Strong expansion
Streak
3 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 249.49% |
| 2024 | 35.56% |
| 2023 | -11.81% |
| 2022 | -25.14% |
| 2021 | 46.00% |
| 2020 | 2.13% |
| 2019 | -10.08% |
| 2018 | -0.43% |
| 2017 | -9.08% |
| 2016 | -12.90% |